Description
What it is / How it works
Investigational triple agonist targeting GLP-1, GIP and glucagon receptors.
Common research interest
Obesity, appetite reduction, glucose regulation and energy expenditure.
Evidence / status
Advanced human clinical development; investigational rather than an approved drug.
